BLUE HORIZON INTERNATIONAL
Blue Horizon International is the world’s leading provider of adult and children’s stem cell therapies. We have safely and efficiently performed more than 4,000 stem cell therapies to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.
As a healthcare management company, Blue Horizon International, LLC offers a revolutionary new hospital concept that focuses on providing the highest quality care and services available in surgical and medical treatments, utilizing the most advanced technologies currently available in areas such as oncology, cardiology, adult stem cell research, orthopedics, and plastic surgery.
The Blue Horizon Charitable Foundation is dedicated to increasing the awareness of global inequalities in healthcare, as well as providing charitable medical care and education to adults and children in impoverished areas. The foundation raises capital in order to support medical centers and clinics by providing medicines vital to basic human survival and by performing advanced medical treatments otherwise not accessible to certain geographic regions. BHCF also supports children around the world who have been orphaned as a result of disease and/or war. In order to raise awareness of these situations, BHCF produces documentary films that bring much needed attention to the plight of those with limited or no access to healthcare. The provision of these resources to less developed areas enables the medically undeserved to benefit from high quality care and treatment.
- Our recent research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance; and presented at the American Academy of Orthopedic Surgeons Annual Meeting (New Orleans, LA, 2018), Adult Stem Cells and Regenerative Medicine Conference, The New York Academy of Sciences (NY, 2019), 7th Annual German Stem Cell Network Conference (Germany, Berlin, 2019).
- Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
- Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
- The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. The study is registered at the ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT03735277).
Please click on the files below to learn more about our research: